Cantargia AB (publ) (CANTAs)

Overview

Cantargia AB (publ) is a pioneering biotechnology firm, committed to the development of antibody-based treatments aimed at life-threatening diseases. Founded in 2009 and headquartered in Lund, Sweden, Cantargia stands at the forefront of biotechnological innovation with its focus on utilising the unique properties of the interleukin-1 receptor accessory protein (IL1RAP). The company has established strategic collaboration agreements with renowned entities like Patheon Biologics B.V. and BioWa Inc. for the manufacturing of their leading compound, CAN04. Additionally, it partners with GEICAM, a Spanish breast cancer group, to enhance the research and development of its oncology portfolio. By targeting both cancer and autoimmune/inflammatory diseases, Cantargia is adamant about delivering novel therapeutic solutions that can significantly improve patient outcomes.

Products and Services

• CAN04 (nadunolimab)

  nadunolimab, also known by its code name CAN04, binds to the IL1RAP element and is currently under Phase II clinical trials. This revolutionary treatment targets several forms of cancer, including pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Developing CAN04 not only illustrates Cantargia's expertise in advanced antibody therapy but also showcases their dedication to combating tough-to-treat cancers.

• CAN10

  CAN10 is a testament to Cantargia's broadening horizon beyond oncology, into autoimmune and inflammatory diseases. This antibody, targeting the same IL1RAP, is in the preclinical phase of development. Its primary focus includes diseases such as systemic sclerosis and myocarditis, demonstrating Cantargia's commitment to addressing a wide range of life-threatening conditions with innovative biotechnology.

• CANxx - IL1RAP-based Antibody Platform

  The CANxx platform represents Cantargia's foundational technology, a sophisticated IL1RAP-based antibody platform. This platform underpins the development of both CAN04 and CAN10, showcasing its versatility and potential for future therapeutic targets. The CANxx platform is a cornerstone of Cantargia's research efforts, enabling the exploration of numerous antibody-based treatments for various diseases.